Abstract:ABSTRACT Background CRISPR-Cas9-based technologies have revolutionized experimental manipulation of mammalian genomes. None-the-less, limitations of the delivery and efficacy of these technologies restrict their application in primary cells. Aims To create an optimized protocol for penetrant, reproducible, and fast targeted insertiondeletion mutation (indel) formation in cell cultures derived from primary cells, using patient-derived glioblastoma (GBM) stem-like cells (GSCs) and human neural stem/progenitor cells (NSCs) for proof-of-concept experiments. Methods We employed transient nucleofection of Cas9:sgRNA ribonucleoprotein complexes using chemically synthesized 2’-O-methyl 3’phosphorothioate-modified sgRNAs and purified Cas9 protein. Indel frequency and size distribution were measured via computational deconvolution of Sanger sequencing trace data. Western blotting was used to evaluate protein loss. RNA-seq in edited NSCs was used to assess gene expression changes resulting from knockout of tumor suppressors commonly altered in GBM. Results We found that with this optimized technique, we can routinely achieve >90% indel formation in only 3 days, without the need to create clonal lines for simple loss-of-function experiments. We observed near-total protein loss of target genes in cell pools. Additionally, we found that this approach allows for the creation of targeted genomic deletions. We also demonstrated the utility of this method for quickly creating a series of gene knockouts that allow for the study of oncogenic activities. Conclusion Our data suggest that this relatively simple method can be used for highly efficient and fast gene knockout, as well as for targeted genomic deletions, even in hyperdiploid cells (such as GSCs). This represents an extremely useful tool for the cancer research community when wishing to inactivate not only coding genes, but also non-coding RNAs, UTRs, enhancers, and promoters. This method can be readily applied to diverse cell types by varying the nucleofection conditions.

Efficient Homology-Directed Gene Editing by CRISPR/Cas9 in Human Stem and Primary Cells Using Tube Electroporation

Highly efficient genome editing via CRISPR–Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage

A Tet-Inducible CRISPR Platform for High-Fidelity Editing of Human Pluripotent Stem Cells

Highly Efficient Genome Editing of Human Hematopoietic Stem Cells Via a Nano-Silicon-blade Delivery Approach.

Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells

Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells

A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures

Crispr/Cas9-Mediated Genome Editing In Human Pluripotent Stem Cells

Efficient Repair of Human Genetic Defect by CRISPR/Cas9-mediated Interlocus Gene Conversion

High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.

CRISPR/Cas9 Mediated Homology Recombination Insertion Knockout of Human SH2B3 Gene

Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders

CRISPR/Cas9 Ribonucleoprotein (RNP) Complex Enables Higher Viability of Transfected Cells in Genome Editing of Acute Myeloid Cells

Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9

Safe scarless cassette-free selection of genome-edited human pluripotent stem cells using temporary drug resistance

Fast-Track and Integration-Free Method of Genome Editing by CRISPR/Cas9 in Murine Pluripotent Stem Cells